Adalimumab is a TNF-α blocker antibody similar in structure and function to natural human IgG1. Even if adalimumab is fully humanized, the development of anti-drug antibodies has been reported in several inflammatory conditions. The objective of our study was to assess the presence of anti-adalimumab antibodies (AAA) and their clinical relevance in a cohort of juvenile idiopathic arthritis (JIA) patients on adalimumab. This is a prospective observational cohort study recruiting JIA children. Experiments were performed using a validated surface plasmon resonance (SPR)-based optical assay (Biacore® T100). Disease activity was evaluated using the Juvenile Arthritis Disease Activity Score with 10 joint count (JADAS-10). The Mann-Whitney U test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher exact test were used to compare data. Pearson's and Spearman's correlation tests were used to determine correlation coefficients for entered variables: demographic, clinical, and serological data. Ten (37%) out of 27 patients included in the study had at least one AAA-positive sample. Patients developed AAA between 3 and 38 months after starting adalimumab. Seven (70%) out of 10 children with AAA positivity experienced at least a relapse compared to 4 (23.5%) out of 17 AAA-negative children (rs0.45, p < 0.017). In conclusion, using an innovative and accurate assay method, we found a high incidence of anti-drug antibodies in a cohort of adalimumab-treated JIA patients observed over a mean period of 40 weeks; the presence of anti-adalimumab antibodies seemed to be related to the number of relapses.
Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis : incidence and clinical correlations / A. Marino, F. Real-Fernández, P. Rovero, T. Giani, I. Pagnini, R. Cimaz, G. Simonini. - In: CLINICAL RHEUMATOLOGY. - ISSN 0770-3198. - 37:5(2018), pp. 1407-1411.
|Titolo:||Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis : incidence and clinical correlations|
|Parole Chiave:||Adalimumab; Immunogenicity; JIA; Surface plasmon resonance|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
Settore MED/38 - Pediatria Generale e Specialistica
|Data di pubblicazione:||2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/s10067-018-4057-7|
|Appare nelle tipologie:||01 - Articolo su periodico|